PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).
Completed
- Conditions
- Metastatic Renal Cell Carcinoma
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 494
- Registration Number
- NCT05858749
- Locations
- 🇺🇸
Pfizer Headquarters, New York, New York, United States
This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.
Completed
- Conditions
- Influenza, HumanCOVID-19
- Interventions
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05858450
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT05857644
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸Genesis Clinical Research, LLC, Tampa, Florida, United States
A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05852340
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease
Phase 3
Completed
- Conditions
- RESPIRATORY SYNCYTIAL VIRUS (RSV)
- Interventions
- Other: PlaceboBiological: RSVpreF
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 886
- Registration Number
- NCT05842967
- Locations
- 🇺🇸
North Alabama Research Center, Athens, Alabama, United States
🇺🇸HOPE Research Institute, Tempe, Arizona, United States
🇺🇸Institute of Human Virology (IHV), Baltimore, Maryland, United States
A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3691397
- Registration Number
- NCT05838664
- Locations
- 🇫🇷
Pfizer Investigational Site, Paris, France
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5279
- Registration Number
- NCT05834348
- Locations
- 🇳🇴
Pfizer Norway, Oslo, Norway
A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults
Phase 1
Completed
- Conditions
- Pneumococcal Disease
- Interventions
- Other: Low dose multivalent pneumococcal conjugate vaccine formulation AOther: Low dose multivalent pneumococcal conjugate vaccine formulation BBiological: Low dose of multivalent pneumococcal conjugate vaccine controlBiological: Standard dose multivalent pneumococcal conjugate vaccine control
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT05831124
- Locations
- 🇺🇸
Centennial Medical Group, Elkridge, Maryland, United States
🇺🇸Rochester Clinical Research, LLC, Rochester, New York, United States
🇺🇸Indago Research & Health Center, Inc, Hialeah, Florida, United States
A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05822440
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Atrial Fibrillation Data Linkage Non-Interventional Study
Not yet recruiting
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 19388
- Registration Number
- NCT05810727
© Copyright 2025. All Rights Reserved by MedPath